IPC leads effort to clarify the genetic architecture of psoriasis

Wednesday, June 20, 2012 03:47 PM

The International Psoriasis Council (IPC) announced the publication of a report in the British Journal of Dermatology’s June edition that summarizes the IPC’s efforts to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis.

The report outlines the progress achieved through the implementation of genome-wide association studies that have highlighted the key pathogenic pathways leading to psoriasis, a disease that affects 1-2% of the world population. The IPC now plans to use this knowledge by conducting a joint scientific, laboratory and patient-related study to better define the genetic architecture of psoriasis. The goal is to help design targeted therapies, the development of markers to monitor disease progression and drug responsiveness to help the vast numbers of patients afflicted with this condition.

"There have been huge advances in the understanding of the inherited basis of psoriasis. But we are only partially complete in clarifying the genetic effect,” said Professor Barker, an IPC board member.

IPC launched the collaboration in October 2011, by convening a workshop that included groups from genetic research laboratories. The collaboration is expected to lay the groundwork for innovative approaches to novel treatment strategies as well as to defining the therapeutic response to treatments in specific psoriasis patients by building a bridge between the genotype and phenotype of the disease.

“This is a landmark effort since it brings together the world’s leading experts in the fields of genetics and psoriasis in a collaborative venture to complete the genetic map of psoriasis, and with it the potential to deliver better future treatments,” said Peter van de Kerkhof, president of IPC.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs